Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.80 - $62.21
Previous CloseN/A
Volume146.24K
Average Volume (3M)907.65K
Market Cap
$3.98B
Enterprise Value$4.37B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 20, 2025EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.35
Shares Outstanding101,122,246
10 Day Avg. Volume857,455
30 Day Avg. Volume907,654
Standard Deviation0.36
R-Squared0.18
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.30K
Enterprise Value/Ebitda-5.19
Forecast
1Y Price Target
$63.56Price Target Upside61.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Biohaven Ltd. News
See All BHVN News
---
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive outcome data demonstrates 50-70% slowing of disease progression in study BHV4157-206-RWE, indicating promising results for troriluzole.
Market OpportunityThe high unmet need for spinocerebellar ataxia treatment presents a significant market opportunity, as there is currently no approved therapy available.
Regulatory ProgressFDA's acceptance of the NDA for troriluzole in spinocerebellar ataxia is seen as an incremental positive for the stock, with the priority review indicating a significant step forward in the approval process.
Bears Say
Previous Regulatory ChallengesThe company previously received a refuse-to-file decision from the FDA in the SCA3 subgroup due to a submission based on post hoc analysis without statistical significance.
Regulatory RisksThe stock is expected to lose previous gains if the FDA issues a Refuse to File.
Strategic DecisionsThere is a 30% chance that after detailed FDA analysis, Biohaven decides the degrader program is a better use of resources and the SCA program is dropped.
---
Ownership Overview
14.80% Insiders
23.27% Mutual Funds
31.66% Other Institutional Investors
15.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $26.80 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $3.98B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 20, 2025 which is in 27 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Nov 12, 2024. The company reported -$1.7 earnings per share for the quarter, beating the consensus estimate of -$1.702 by $0.002.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -1.58.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 101,122,246 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.7 in its last earnings report, beating expectations of -$1.702. Following the earnings report the stock price went down -2.621%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
---
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.56 (61.98% Upside)
$63.56 (61.98% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.72%
12-Months-Change
Fundamentals
Return on Equity
-265.45%
Trailing 12-Months
Asset Growth
33.39%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$63.56
▲(61.98% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+54.61%
reiterated a buy rating 10 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +54.61% per trade.
---